27 related articles for article (PubMed ID: 38687638)
1. Discovery of
Liu L; Zhao L; Yang L; Chai M; Liu Z; Ma N; Wang Y; Wu Q; Guo J; Zhou F; Huang W; Ren X; Wang J; Ding M; Wang Z; Ding K
J Med Chem; 2024 May; 67(10):8043-8059. PubMed ID: 38730324
[TBL] [Abstract][Full Text] [Related]
2. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.
Li C; Qiao Y; Jiang X; Liu L; Zheng Y; Qiu Y; Cheng C; Zhou F; Zhou Y; Huang W; Ren X; Wang Y; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2023 Sep; 66(17):12432-12445. PubMed ID: 37605297
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
Hanley RP; Nie DY; Tabor JR; Li F; Sobh A; Xu C; Barker NK; Dilworth D; Hajian T; Gibson E; Szewczyk MM; Brown PJ; Barsyte-Lovejoy D; Herring LE; Wang GG; Licht JD; Vedadi M; Arrowsmith CH; James LI
J Am Chem Soc; 2023 Apr; 145(14):8176-8188. PubMed ID: 36976643
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
6. Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
Liu W; Bai Y; Zhou L; Jin J; Zhang M; Wang Y; Lin R; Huang W; Ren X; Ma N; Zhou F; Wang Z; Ding K
Eur J Med Chem; 2024 Jan; 264():115974. PubMed ID: 38007910
[TBL] [Abstract][Full Text] [Related]
7. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
[TBL] [Abstract][Full Text] [Related]
8. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
Sankaran SM; Wilkinson AW; Elias JE; Gozani O
J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
[TBL] [Abstract][Full Text] [Related]
9. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract][Full Text] [Related]
10. Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
Ma Z; Bolinger AA; Chen H; Zhou J
J Med Chem; 2023 Aug; 66(16):10991-11026. PubMed ID: 37578463
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
Zhang L; Zha X
Eur J Med Chem; 2023 Mar; 250():115232. PubMed ID: 36863225
[TBL] [Abstract][Full Text] [Related]
12. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
